The E-cadherin-catenin complex, by mediating intercellular adhesion, regulates the architectural integrity of epithelia. Down-regulation of its expression is thought to contribute to invasion of carcinoma cells. To investigate the involvement of the E-cadherin-catenin adhesion system in the progression of human bronchopulmonary carcinomas, we compared the immunohistochemical distribution of E-cadherin, alpha-catenin, and beta-catenin in four human bronchial cancer cell lines with different invasive abilities and in 44 primary bronchopulmonary tumors. Although invasive bronchial cell lines did not express E-cadherin and alpha-catenin, complete down-regulation of cadherin-catenin complex expression was a rare event in vivo in bronchopulmonary carcinomas. Nevertheless, a spotty and cytoplasmic pattern of E-cadherin and catenins was observed in 32 primary tumors, only in invasive tumor clusters. Immunoprecipitation experiments showed that this redistribution was not related to a disruption of cadherin-catenin interaction but to down-regulated tyrosine phosphorylation of E-cadherin. We conclude that loss of E-cadherin and/or catenins is not a prominent early event in the invasive progression of human bronchopulmonary carcinomas in vivo. The decreased tyrosine phosphorylation of E-cadherin may reflect a loss of functionality of the complex and implicates a major role in tumor invasion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853397PMC
http://dx.doi.org/10.1016/s0002-9440(10)65740-9DOI Listing

Publication Analysis

Top Keywords

bronchopulmonary carcinomas
16
tyrosine phosphorylation
12
phosphorylation e-cadherin
12
human bronchopulmonary
12
e-cadherin-catenin adhesion
8
down-regulated tyrosine
8
progression human
8
e-cadherin alpha-catenin
8
cell lines
8
tumors invasive
8

Similar Publications

Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).

View Article and Find Full Text PDF

Central nervous system (CNS) metastases of atypical carcinoid tumors are exceptionally rare. Isolated studies suggest a survival benefit in patients who receive whole-brain radiotherapy (WBRT); however, it has been known to have detrimental effects on long-term memory and executive function. Here, we present a case of a patient initially diagnosed with stage IIB bronchopulmonary carcinoid who later developed hepatic and intracranial metastases despite receiving adjuvant systemic therapy over a two-year period.

View Article and Find Full Text PDF

Diagnostic issues in neuroendocrine neoplasms of the lung.

Pathologie (Heidelb)

November 2024

Department of Pathology, TUM School of Medicine and Health, Trogerstr. 18, 81675, Munich, Germany.

Article Synopsis
  • Bronchopulmonary neuroendocrine neoplasms (BP-NENs) make up about 30% of all neuroendocrine neoplasms (NENs) and show similarities to gastroenteropancreatic NENs (GEP-NENs) but differ in classification.
  • BP-NETs (previously known as carcinoids) are classified into typical (TC) and atypical carcinoids (AC), with the new WHO 2022 classification introducing NET G1 and G2 correspondingly.
  • The review emphasizes the significance of the Ki-67 index for accurately classifying BP-NETs, noting that it is not included in their current classification criteria despite its relevance in
View Article and Find Full Text PDF

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids.

Front Endocrinol (Lausanne)

July 2024

Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS, Istituto Auxologico Italiano, Milan, Italy.

Article Synopsis
  • Lung carcinoids (LCs) are rare neuroendocrine tumors in the lungs, representing 20-25% of neuroendocrine tumors and 1-2% of lung cancers, making anti-angiogenic therapies like axitinib (AXI) potential treatment options.
  • In a study, three LC cell lines were treated with AXI to assess its long-term effects, focusing on cell cycle changes, apoptosis, and mechanisms like senescence and mitotic catastrophe.
  • Results indicated that AXI effectively inhibits tumor growth by causing indirect DNA damage, but its efficacy may decrease if DNA damage is repaired, emphasizing the importance of DNA damage in its therapeutic action.
View Article and Find Full Text PDF

A 72-year-old man with productive cough and wheezing was referred to our institution for a growing mass shadow and central bronchiectasis in the right lower lobe on computed tomography. Based on the symptoms, elevated Aspergillus-specific immunoglobulin E levels, and radiological findings, allergic bronchopulmonary mycosis (ABPM) was suspected according to the Japanese clinical diagnostic criteria. The patient refused bronchoscopic examination, and oral prednisolone (0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!